STRASBOURG, France--(BUSINESS WIRE)--Regulatory News:
Transgene (Euronext Paris:TNG), a company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases, announced the new composition of its board of directors and the appointment of new statutory auditors following yesterday’s annual shareholders’ meeting (AGM).
The AGM appointed Mr Antoine Béret1 as an independent director, to replace Mr Arnaud Fayet who did not seek a renewal of his term.
“We warmly thank Arnaud Fayet who has accompanied us since 2000, including as chairman of our audit committee. His strong professional skills, his availability, his open mindset and his human qualities have been precious to us over the course of these years,” said Philippe Archinard, Chairman and CEO of Transgene. He added: “We are pleased to welcome Antoine Béret. He brings us decades of experience in creating and directing businesses in our industry and we look forward to benefiting from them over the next steps of our development.”
In addition, the AGM has:
- renewed the mandates of Mr Jean-Luc Bélingard and three independent directors: Prof. Laurence Zitvogel, MD, Jean-Pierre Bizzari, MD, and Mr Jean-François Labbé. The board of directors is composed of 10 members, including six independent directors;
- renewed the mandates of Ernst et Young & Autres and Auditex as primary and substitute statutory auditors respectively and appointed two new statutory auditors: Grant Thornton (primary) and IGEC company (substitute); and
- voted the other resolutions submitted, in accordance with the recommendations of the Board of Directors.
Transgene S.A. (Euronext: TNG), part of Institut Mérieux, is a publicly traded French biopharmaceutical company focused on designing and developing targeted immunotherapies for the treatment of cancer and infectious diseases. Transgene’s programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The Company’s two lead clinical-stage programs are: TG4010 for non-small cell lung cancer and Pexa-Vec for liver cancer. The Company has several other programs in clinical and pre-clinical development. Transgene is based in Strasbourg, France, and has additional operations in Lyon, as well as satellite offices in China and the U.S. Additional information about Transgene is available at www.transgene.fr.
1 Antoine Béret (71 years old, French citizen), has been Chief Executive Officer (CEO) of Genoscience Pharma SAS since 2012 and Chairman of Axenis. He graduated from Ecole Nationale des Ponts et Chaussées and Ecole Polytechnique. M. Béret co-founded several companies specializing in biomedicine, including Trophos where he served as CEO until 2008 and Immunotech that he directed until 1996 when Immunotech was acquired by Coulter Inc. He started his career as a civil engineer in both public and private sectors, then has been project manager in charge of funding industrial companies at Crédit National and directed and invested as a ‘business angel’ TxCell in 2001-2002.